Related Experiment Videos
[The study of drug sensitivity on newly established three choriocarcinoma cell lines]
Abstract:
After serial transplantation in nude mice, we had established three new human choriocarcinoma cell lines (NaUCC-1,2 and 3). These three cell lines and BeWo were examined for sensitivity to Act-D, MTX and the combined agents (Act-D + MTX) 3H-Act-D uptake and 3H-MTX uptake, and were compared for each treatment. NaUCC-1 showed low sensitivity to MTX (p less than 0.05), but showed high sensitivity to Act-D (p less than 0.05). BeWo showed low sensitivity to Act-D (p less than 0.05). In examining sensitivity to the combined agents (Act-D+ MTX), the sensitivity of NaUCC-2 to Act-D was decreased (p less than 0.05) by MTX added at the same time. In the 3H-Act-D uptake experiment, NaUCC-1 did uptake a relatively larger amount of 3H-Act-D (p less than 0.01) and BeWo a smaller amount of it (p less than 0.05). In the 3H-MTX uptake experiment, NaUCC-1 did uptake a relatively smaller amount of 3H-MTX (p less than 0.05), but NaUCC-2 uptook a larger amount of it (p less than 0.005). NaUCC-1 established from the patient in whom tumor cells were resistant to treatment, had a low response to MTX. NaUCC-2 was established from the patient in whom it was found that MTX inhibits the Act-D effect on tumor cells. In the study of combined agents in NaUCC-2, the growth inhibition effect of Act-D was suppressed by the MTX added.
Insights
New human choriocarcinoma cell lines (NaUCC-1, -2, -3) were developed. NaUCC-1 showed high sensitivity to Actinomycin-D (Act-D) but low sensitivity to Methotrexate (MTX), while MTX inhibited Act-D
Area of Science:
- * Oncology
- * Pharmacology
Context:
- * Established three new human choriocarcinoma cell lines (NaUCC-1, -2, -3) via serial transplantation in nude mice.
- * Investigated drug sensitivity and uptake mechanisms of novel cell lines and BeWo.
- * Explored differential responses to Actinomycin-D (Act-D) and Methotrexate (MTX), individually and in combination.
Purpose:
- * To characterize the chemosensitivity profiles of newly established human choriocarcinoma cell lines.
- * To compare the uptake of 3H-Actinomycin-D (3H-Act-D) and 3H-Methotrexate (3H-MTX) in these cell lines.
- * To evaluate the combined effects of Act-D and MTX on choriocarcinoma cell growth and drug uptake.
Summary:
- * NaUCC-1 exhibited high sensitivity to Act-D and low sensitivity to MTX, with increased 3H-Act-D and decreased 3H-MTX uptake.
- * NaUCC-2 showed reduced sensitivity to Act-D when combined with MTX, indicating potential drug-drug interactions.
- * BeWo demonstrated low sensitivity to Act-D and lower 3H-Act-D uptake compared to NaUCC-1.
- * NaUCC-1, derived from a treatment-resistant patient, showed poor MTX response, correlating with its uptake profile.
Impact:
- * Provides valuable insights into the differential drug responses and mechanisms of novel choriocarcinoma models.
- * Highlights potential therapeutic strategies and challenges in combining Act-D and MTX for choriocarcinoma treatment.
- * Contributes to the understanding of drug resistance and sensitivity in gynecological cancers.